COGT Stock Price, Cogent Biosciences, Inc. Quote, Chart

Market Summary

USD7.72+0.37

Market Closed

5.03%

COGT Stock Price

View Fullscreen

COGT RSI Chart

COGT Valuation

Market Cap

702.8M

Price/Earnings (Trailing)

-3.31

Price/Sales (Trailing)

94.14

Price/Free Cashflow

-4.17

COGT Price/Sales (Trailing)

COGT Profitability

Return on Equity

-50.23%

Return on Assets

-44.55%

Free Cashflow Yield

-23.96%

COGT Fundamentals

COGT Revenue

Revenue (TTM)

7.9M

COGT Earnings

Earnings (TTM)

-212.1M

Earnings Growth (Yr)

-51.09%

Earnings Growth (Qtr)

-7.24%

Breaking Down COGT Revenue

Last 7 days

-5.3%

Last 30 days

12.9%

Last 90 days

-15.5%

Trailing 12 Months

-38.2%

How does COGT drawdown profile look like?

COGT Financial Health

Current Ratio

12.05

COGT Investor Care

Shares Dilution (1Y)

34.77%

Diluted EPS (TTM)

-2.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	26.5M	23.9M	23.2M	7.9M
2019	10.6M	12.0M	11.0M	22.5M
2018	8.8M	8.3M	8.1M	9.7M
2017	0	0	0	8.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cogent Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	fairmount funds management llc	acquired	-	-	286,851	-
Mar 28, 2024	fairmount funds management llc	sold	-	-	-286,851	-
Feb 16, 2024	fairmount funds management llc	acquired	8,750,000	7.5	1,166,670	-
Jun 09, 2023	fairmount funds management llc	bought	9,600,000	12.00	800,000	-
Jun 30, 2022	sachs jessica	acquired	4,599	7.395	622	chief medical officer
Jun 16, 2022	fairmount funds management llc	bought	9,900,000	8.25	1,200,000	-
Dec 31, 2021	sachs jessica	acquired	4,594	6.817	674	chief medical officer
Apr 26, 2021	green john l.	sold	-157,823	8.86	-17,813	chief financial officer
Feb 25, 2021	green john l.	acquired	-	-	524	chief financial officer
Dec 01, 2020	green john l.	acquired	-	-	1,748	chief financial officer

Which funds bought or sold COGT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	Nuveen Asset Management, LLC	added	317	5,429,330	6,868,450	-%
May 13, 2024	PLATINUM INVESTMENT MANAGEMENT LTD	reduced	-60.84	-1,545,100	1,251,630	0.05%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	2.8	1,777,660	11,943,900	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	1,040	1,860,000	2,014,000	-%
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.85	32,310	275,083	-%
May 13, 2024	Pathstone Holdings, LLC	sold off	-100	-103,481	-	-%
May 13, 2024	Jump Financial, LLC	reduced	-57.93	-76,378	70,728	-%
May 13, 2024	READYSTATE ASSET MANAGEMENT LP	new	-	3,609,980	3,609,980	0.05%
May 13, 2024	NEOS Investment Management LLC	added	41.47	46,919	122,983	0.01%
May 13, 2024	UBS Group AG	added	89.53	1,559,200	2,896,350	-%

Are Funds Buying or Selling COGT?

Are funds buying COGT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own COGT

No. of Funds

Unveiling Cogent Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	fairmount funds management llc	9.90%	9,986,556	SC 13D/A
Mar 27, 2024	fairmount funds management llc	9.90%	9,986,556	SC 13D/A
Feb 16, 2024	fairmount funds management llc	18.89%	23,079,141	SC 13D/A
Feb 14, 2024	kynam capital management, lp	6.8%	5,854,766	SC 13G
Feb 14, 2024	commodore capital lp	7.1%	6,172,086	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	6.0%	5,191,448	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	9.99%	9,038,844	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	5.27%	4,534,655	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G

Recent SEC filings of Cogent Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 10, 2024	EFFECT	EFFECT
Apr 08, 2024	CORRESP	CORRESP
Apr 05, 2024	UPLOAD	UPLOAD
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Cogent Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.91	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.98	9.54	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.39	14.63	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.02	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Cogent Biosciences, Inc. News

Latest updates

Cogent Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																(In Millions)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	-100.0%	-	0.00	1.00	7.00	15.00	1.00	3.00	3.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Costs and Expenses	-80.1%	11.00	58.00	8.00	13.00	13.00	13.00	14.00	15.00	13.00	13.00	11.00	-	-	-	-	-
S&GA Expenses	-4.5%	5.00	6.00	3.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	-	-	-	-
R&D Expenses	22.1%	6.00	5.00	5.00	9.00	10.00	10.00	11.00	12.00	11.00	10.00	9.00	-	-	-	-	-
Net Income	77.3%	-11.34	-49.98	-7.39	-6.09	2.00	-11.92	-10.52	-11.69	-8.61	-10.17	-9.02	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	51.9%	476	313	355	392	263	301	332	366	207	232	215	229	238	251	140	31.00	39.00	49.00	58.00	69.00	81.00
Current Assets	63.2%	442	271	286	335	226	265	296	331	195	223	208	221	232	245	133	24.00	31.00	41.00	48.00	59.00	70.00
Cash Equivalents	305.4%	216	53.00	87.00	214	161	140	142	327	192	221	204	219	232	243	131	23.00	31.00	39.00	47.00	57.00	60.00
Net PPE	-6.3%	8.00	8.00	9.00	9.00	9.00	8.00	7.00	4.00	2.00	2.00	1.00	0.00	0.00	0.00	0.00	1.00	2.00	2.00	2.00	3.00	3.00
Liabilities	-3.3%	54.00	56.00	53.00	44.00	40.00	45.00	42.00	47.00	19.00	18.00	18.00	16.00	11.00	16.00	24.00	12.00	13.00	18.00	29.00	30.00	32.00
Current Liabilities	-3.9%	37.00	38.00	35.00	26.00	21.00	27.00	24.00	28.00	18.00	17.00	17.00	14.00	8.00	13.00	20.00	8.00	9.00	13.00	24.00	24.00	26.00
Shareholder's Equity	63.8%	422	258	303	348	224	256	290	319	188	214	197	213	227	235	-	19.00	26.00	32.00	29.00	40.00	49.00
Retained Earnings	-9.7%	-662	-603	-549	-493	-449	-411	-371	-336	-301	-270	-246	-226	-210	-198	-187	-137	-129	-123	-126	-114	-103
Additional Paid-In Capital	7.6%	862	801	792	780	611	601	596	584	411	400	358	354	342	322	165	157	156	156	155	154	153
Shares Outstanding	11.0%	96.00	86.00	86.00	85.00	71.00	70.00	55.00	47.00	45.00	39.00	38.00	38.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	968	-	-	-	568	-	-	-	311	-	-	-	11.00	-	-	-	40.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-19.2%	-52,529	-44,070	-37,971	-32,066	-39,517	-29,408	-34,440	-26,456	-28,334	-20,777	-14,109	-12,511	-11,366	-9,366	-10,267	-8,324	-7,893	-8,445	-10,207	-11,344	-11,518
Share Based Compensation	6.1%	9,393	8,851	8,757	7,163	5,850	5,037	4,622	4,534	4,175	3,852	3,463	2,590	1,781	866	3,512	870	769	842	788	885	726
Cashflow From Investing	-90.0%	1,044	10,489	-90,536	-77,661	59,884	28,411	-151,544	-1,144	-441	-433	-1,163	-	-	-	-	-	-	-13.00	226	7,996	14,950
Cashflow From Financing	-	214,057	-	1,000	162,091	445	315	990	162,115	138	38,006	55.00	-	-85.00	122,136	109,925	62.00	73.00	-	-	97.00	11.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

COGT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 52,705	$ 36,038
General and administrative	9,699	7,199
Total operating expenses	62,404	43,237
Loss from operations	(62,404)	(43,237)
Other income:
Interest income	4,057	2,268
Other income, net	(1)	682
Change in fair value of CVR liability	0	1,700
Total other income, net	4,056	4,650
Net loss	$ (58,348)	$ (38,587)
Net loss per share attributable to common stockholders, basic	$ (0.62)	$ (0.55)
Net loss per share attributable to common stockholders, diluted	$ (0.62)	$ (0.55)
Weighted average common shares outstanding, basic	94,804,659	70,734,950
Weighted average common shares outstanding, diluted	94,804,659	70,734,950
Comprehensive loss:
Net loss	$ (58,348)	$ (38,587)
Other comprehensive loss
Net unrealized losses on marketable securities	(285)	120
Total other comprehensive loss	(285)	120
Comprehensive loss	$ (58,633)	$ (38,467)

COGT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 215,801	$ 53,229
Short-term marketable securities	219,939	212,481
Prepaid expenses and other current assets	6,163	5,061
Total current assets	441,903	270,771
Long-term marketable securities	0	7,460
Operating lease, right-of-use assets	21,531	21,998
Property and equipment, net	7,815	8,344
Other assets	4,862	4,864
Total assets	476,111	313,437
Current liabilities:
Accounts payable	15,565	10,655
Accrued expenses and other current liabilities	19,689	26,127
Operating lease liabilities	1,432	1,386
Total current liabilities	36,686	38,168
Operating lease liabilities, net of current portion	17,091	17,467
Total liabilities	53,777	55,635
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, value
Common stock, $0.001 par value; 150,000,000 shares authorized; 95,613,396 shares and 86,124,249 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	96	86
Additional paid-in capital	862,096	801,059
Accumulated other comprehensive income (loss)	(39)	246
Accumulated deficit	(661,972)	(603,624)
Total stockholders’ equity	422,334	257,802
Total liabilities and stockholders’ equity	476,111	313,437
Series A Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value	60,035	60,035
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value	$ 162,118

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Andrew R. Robbins M.B.A.
WEBSITE	cogentbio.com
INDUSTRY	Biotechnology
EMPLOYEES	138

Cogent Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Cogent Biosciences, Inc.? What does COGT stand for in stocks?

COGT is the stock ticker symbol of Cogent Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cogent Biosciences, Inc. (COGT)?

As of Tue May 14 2024, market cap of Cogent Biosciences, Inc. is 702.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COGT stock?

You can check COGT's fair value in chart for subscribers.

What is the fair value of COGT stock?

You can check COGT's fair value in chart for subscribers. The fair value of Cogent Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cogent Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for COGT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cogent Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether COGT is over valued or under valued. Whether Cogent Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Cogent Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COGT.

What is Cogent Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, COGT's PE ratio (Price to Earnings) is -3.31 and Price to Sales (PS) ratio is 94.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COGT PE ratio will change depending on the future growth rate expectations of investors.